Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

423
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
423
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

7
Body:The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
7
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

14
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
14
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

10
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
10
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

103
Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least...
103
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

14
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
14

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem Helix.

The Journal of infectious diseases·2026
Same author

Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma.

Blood advances·2026
Same author

Comprehensive Lipidomic Profiling Reveals Distinct Metabolic Remodeling during Differentiation of Human Monocyte-Derived Macrophages.

Journal of proteome research·2026
Same author

Advancing Precision Dosing of 5-FU: Population PK Model Development, Limited Sampling Strategies, and Fit-for-Use Application.

Clinical pharmacokinetics·2026
Same author

Intrapulmonary penetration of ceftolozane/tazobactam and ceftazidime/avibactam administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial.

Critical care (London, England)·2026
Same author

Mathematical modeling of ribosome competition informs testable treatment strategies for drug-tolerant cancer persister cells.

iScience·2026

Related Experiment Video

Updated: Oct 9, 2025

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.1K

Untangling Absorption Mechanisms and Variability in Bioequivalence Studies Using Population Analysis.

Carolina Ameijeiras Rodríguez1, Sara Carolina Henriques2,3, Aymara Sancho-Araiz4,5

  • 1MedInUP-Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal. carolinaamei@gmail.com.

Pharmaceutical Research
|December 21, 2021
PubMed
Summary

Optimizing crossover study designs can help control inter-individual variability (IIV) in bioequivalence studies. Standardizing water intake may reduce variability in Cmax and AUC, particularly for certain drug classes.

Keywords:
BDDCSbioequivalencepopulation pharmacokinetics

More Related Videos

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

32.5K
An In Vivo Method for Evaluating the Gut-Blood Barrier and Liver Metabolism of Microbiota Products
14:54

An In Vivo Method for Evaluating the Gut-Blood Barrier and Liver Metabolism of Microbiota Products

Published on: October 20, 2018

8.6K

Related Experiment Videos

Last Updated: Oct 9, 2025

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.1K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

32.5K
An In Vivo Method for Evaluating the Gut-Blood Barrier and Liver Metabolism of Microbiota Products
14:54

An In Vivo Method for Evaluating the Gut-Blood Barrier and Liver Metabolism of Microbiota Products

Published on: October 20, 2018

8.6K

Area of Science:

  • Pharmacokinetics and Drug Metabolism
  • Clinical Pharmacology
  • Bioequivalence Study Design

Background:

  • Inter-individual variability (IIV) and inter-occasion variability (IOV) are inherent challenges in bioequivalence studies.
  • High IOV can impede the successful demonstration of bioequivalence, even with stringent study controls.
  • Optimizing study design is crucial for managing variability in drug development.

Purpose of the Study:

  • To investigate methods for controlling inter-individual variability (IIV) by optimizing crossover study designs.
  • To analyze the influence of biopharmaceutical properties on pharmacokinetic variability.
  • To assess the impact of water intake on drug absorption and variability.

Main Methods:

  • Population pharmacokinetic (popPK) models were developed using data from 18 bioequivalence studies.
  • Analyzed 14 drugs, characterizing absorption and disposition processes.
  • Estimated IOV and evaluated correlations with drug properties using the Biopharmaceutics Drug Disposition Classification System (BDDCS).

Main Results:

  • PopPK models successfully described plasma-pharmacokinetic profiles for all 14 drugs.
  • Variability was highest in absorption rate, absorption duration, relative bioavailability, and latency time.
  • Higher residual variability (RUV) was observed for BDDCS Class 2 drugs compared to Class 1 and 3.

Conclusions:

  • Drug absorption parameters exhibit significant variability.
  • Standardizing water intake (240 mL) with immediate-release products can standardize gastric emptying.
  • Standardizing water intake until expected Tmax is recommended to reduce Cmax and AUC variability, especially for BDDCS Classes 2 and 4.